Diagnostic Protein Articles & Analysis
11 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the expansion of its Hepatitis B research portfolio with a comprehensive range of sensitive and specific Hepatitis B Virus Surface Antigen L-proteins. ...
The company's portfolio includes immune checkpoint proteins, CAR-T cell targets, CD antigens, fluorescent-labeled recombinant proteins, PROTAC targets, and more. ...
In addition, Creative Diagnostics possesses a variety of ELISA kits for the detection of hundreds of different proteins and molecules, including cytokines, growth factors, markers of infectious diseases, diabetes and tumors, small molecular drugs, and more. ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. ...
In the meantime, ongoing research is performed to further understand the epidemiology, source of infection, and mode of transmission of MPXV. Creative Diagnostics now offers a series of reagent solutions for global scientists studying the monkeypox virus, including various antigens and antibodies, such as Mouse Anti-MPXV M1R Monoclonal Antibody for ELISA/Neut, and Monkeypox Virus ...
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. ...
In the AutoPilot study, the high diagnostic performance of the host-response protein signature underlying MeMed’s technology was validated in a broad pediatric cohort (n=1,008; >90 days to 18 years). ...
ByMeMed
As a leader in the development of CRISPR products, Mammoth Biosciences has generated international recognition for its unique approach to diagnostics, genome editing, and protein discovery. The company has made immense strides this year in building its CRISPR toolkit, for example with the exclusive licensing and development of the Cas? family of ...
In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest is focused on developing a complete understanding of the human plasma proteome. This unique proteomic platform of targets will help Grifols and Alkahest to unlock new therapeutics and diagnostics, develop new plasma proteins, new indications for ...
Grifols increases its revenues by 12% to EUR 1,293 million The Bioscience Division leads growth, increasing revenues by 13.6% (10.9% cc) to EUR 1,040 million, driven mainly by the demand for strong key proteins, especially with immunoglobulins Diagnostic and Hospital Division revenues remain stable at EUR 168 million (1.4%; -0.3% cc) and EUR 31 million ...
The blood analysis was carried out using PerkinElmer's BioXPRESSION™ Biomarker platform and Predictive Diagnostic's proprietary BAMF™ technology to identify patterns of proteins and peptides that distinguish Alzheimer's disease patients from those without clinical signs. ...